Liver injury in COVID-19: A minireview

World J Clin Cases. 2020 Oct 6;8(19):4303-4310. doi: 10.12998/wjcc.v8.i19.4303.

Abstract

In December 2019, an outbreak of unexplained pneumonia was reported in Wuhan, China. The World Health Organization officially named this disease as novel coronavirus disease 2019 (COVID-19). Liver injury was observed in patients with COVID-19, and its severity varied depending on disease severity, geographical area, and patient age. Systemic inflammatory response, immune damage, ischemia-reperfusion injury, viral direct damage, drug induce, mechanical ventilation, and underlying diseases may contribute to liver injury. Although, in most cases, mild liver dysfunction is observed, which is usually temporary and does not require special treatment, the importance of monitoring liver injury should be emphasized for doctors. The risk of COVID-19 infection of liver transplantation recipients caused more and more concerns. In this article, we aimed to review the available literature on liver injury in COVID-19 to highlight the importance of monitoring and treating liver injury in COVID-19.

Keywords: COVID-19; Hepatoprotective drugs; Liver injury; Novel coronavirus; Pandemic; SARS-CoV-2.

Publication types

  • Review